These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 18041880)
81. Observational studies on the risk of cancer associated with tumor necrosis factor inhibitors in rheumatoid arthritis: a review of their methodologies and results. Solomon DH; Mercer E; Kavanaugh A Arthritis Rheum; 2012 Jan; 64(1):21-32. PubMed ID: 21898354 [No Abstract] [Full Text] [Related]
82. Physico-chemical characteristics of TNFα blockers and their effectiveness in the treatment of rheumatoid arthritis: the theoretical and real worlds. Minota S Mod Rheumatol; 2013 Sep; 23(5):1034-6. PubMed ID: 22956242 [No Abstract] [Full Text] [Related]
83. Cytotoxic T-lymphocyte antigen 4-immunoglobulin in rheumatoid arthritis. Kremer JM Rheum Dis Clin North Am; 2004 May; 30(2):381-91, viii. PubMed ID: 15172047 [TBL] [Abstract][Full Text] [Related]
84. First-in-class biologic to enter rheumatoid arthritis fray. Garber K Nat Biotechnol; 2005 Nov; 23(11):1323-4. PubMed ID: 16273043 [No Abstract] [Full Text] [Related]
85. [State-of-the-art biological therapy of rheumatoid arthritis]. Sigidin IaA; Lukina GV Vestn Ross Akad Med Nauk; 2008; (6):19-24. PubMed ID: 18652199 [TBL] [Abstract][Full Text] [Related]
86. The impact of abatacept treatment on the vasculature in patients with rheumatoid arthritis. Sandoo A; Kitas GD Clin Exp Rheumatol; 2015; 33(4):589. PubMed ID: 26121184 [No Abstract] [Full Text] [Related]
87. [Rheumatoid polyarthritis: a new treatment]. Perspect Infirm; 2010; 7(5):46-7. PubMed ID: 21744636 [No Abstract] [Full Text] [Related]
88. New risks with newer rheumatoid arthritis drugs. Mayo Clin Health Lett; 2006 Nov; 24(11):4. PubMed ID: 17225261 [No Abstract] [Full Text] [Related]
89. New strategies for patenting biological medicines used in rheumatoid arthritis treatment. Oliveira RA; Fierro IM Expert Opin Ther Pat; 2018 Aug; 28(8):635-646. PubMed ID: 30047807 [TBL] [Abstract][Full Text] [Related]
90. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010. Furst DE; Keystone EC; Braun J; Breedveld FC; Burmester GR; De Benedetti F; Dörner T; Emery P; Fleischmann R; Gibofsky A; Kalden JR; Kavanaugh A; Kirkham B; Mease P; Sieper J; Singer NG; Smolen JS; Van Riel PL; Weisman MH; Winthrop K Ann Rheum Dis; 2011 Mar; 70 Suppl 1():i2-36. PubMed ID: 21339216 [No Abstract] [Full Text] [Related]
91. [First scientific meeting of CRI (Rheumatism and Inflammation Club) under the patronage of FNSIM (French National Society of Internal Medicine) and FSR(French Society of Rheumatology) Paris, May 4, 2002]. Grateau G; Geffray L; Veyssier-Belot C Rev Med Interne; 2002 Oct; 23(10):805-7. PubMed ID: 12428480 [No Abstract] [Full Text] [Related]
92. Therapy: what should we do after the failure of a first anti-TNF? Deighton C Nat Rev Rheumatol; 2009 Nov; 5(11):596-7. PubMed ID: 19865088 [No Abstract] [Full Text] [Related]
96. One more rheumatoid drug. Health News; 2004 Jan; 10(1):8. PubMed ID: 15002381 [No Abstract] [Full Text] [Related]
97. Reply: To PMID 25371395. Gregersen PK; Oswald M; Curran M; Carulli J; Arthritis Rheumatol; 2015 May; 67(8):2277. PubMed ID: 25989099 [No Abstract] [Full Text] [Related]
98. A signal achievement in the treatment of arthritis. Cron RQ Arthritis Rheum; 2005 Aug; 52(8):2229-32. PubMed ID: 16052533 [No Abstract] [Full Text] [Related]
99. Novel approaches to discovery of biomarkers in rheumatoid arthritis: comment on the article by Oswald et al. Hudson M; Baron M; Colmegna I; Bernatsky S; Klein Oros K; Pastinen T; Greenwood C Arthritis Rheumatol; 2015 May; 67(8):2276-7. PubMed ID: 25988805 [No Abstract] [Full Text] [Related]
100. [Recommendations on the use of rituximab for patients with rheumatoid arthritis]. Rubbert-Roth A; Burmester G; Z Rheumatol; 2008 Nov; 67(7):609-13. PubMed ID: 18830700 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]